India could soon see its largest-ever pharma deal as the 10th biggest pharma company by revenues -- Torrent -- is trying to buy the fourth largest one -- Cipla. But, is the bullet too big to bite for Torrent? Is the funding feasible? Will the compatibility not of portfolio but of philosophy, and people, be a challenge? Will Torrent’s M&A ambition extend beyond pharma and power to possibly once again finance? Host Anupriya Nair solves this complex bond along with Economic Times’ Arijit Barman, Kiran Somvanshi & Sangita Mehta in this episode of The Morning Brief podcast. Tune in!

To know more about the Cipla pharmaceuticals, you can read this story by Arujit Barman: Torrent in top gear to close out Cipla buyout, in talks with PEs, banks for funds or listen to this episode of The Morning Brief podcast: Cipla Saga - Did The Doctor Prescribe A Sale?

You can follow our host Anupriya Nair on her social media: Twitter & Linkedin

Catch the latest episode of ‘The Morning Brief’ on ET Play, The Economic Times Online, Spotify, Apple Podcasts, JioSaavn, Amazon Music and Google Podcasts.

Credits: ET Now, trendlyne

See omnystudio.com/listener for privacy information.

Tight-lipped but Turbo Torrent Guns For Cipla

The Morning Brief

Tight-lipped but Turbo Torrent Guns For Cipla